MDCX
Medicus Pharma Ltd. Common StockMDCX
MDCX
About: Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
Employees: 12
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
202% more capital invested
Capital invested by funds: $3.74M [Q4 2024] → $11.3M (+$7.57M) [Q1 2025]
100% more funds holding
Funds holding: 3 [Q4 2024] → 6 (+3) [Q1 2025]
9.95% more ownership
Funds ownership: 12.72% [Q4 2024] → 22.67% (+9.95%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
720%
upside
Avg. target
$24
863%
upside
High target
$27
1,007%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 1,007%upside $27 | Buy Maintained | 9 Jul 2025 |
Maxim Group Jason McCarthy | 720%upside $20 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 6 articles about MDCX published over the past 30 days
Neutral
Newsfile Corp
1 week ago
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
The Company added Congresswoman Cathy McMorris Rodgers & Ajay Raju, Esq. to the Board of Directors.
Neutral
Newsfile Corp
1 week ago
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
Executive Chairman & CEO of the Company to Participate in a Fireside Chat Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza Bokhari, Executive Chairman and CEO, at the BTIG Virtual Biotech Conference 2025.
Positive
Proactive Investors
3 weeks ago
Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) announced that it has submitted a formal request to the US Food and Drug Administration (FDA) for a Type C meeting to discuss the clinical development pathway for its dissolvable doxorubicin-containing microneedle array (D-MNA) product targeting basal cell carcinoma (BCC) of the skin. The company is seeking a meeting during the week of October 6, aiming to gain the agency's approval to fast-track the program and seek feedback on future clinical plans.
Neutral
Newsfile Corp
3 weeks ago
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
The Company's aim is to seek FDA consent to fast track the Clinical Development Program to treat Basal Cell Carcinoma (BCC) of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA) Philadelphia, Pennsylvania--(Newsfile Corp. - July 8, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive package to the United States Food and Drug Administration (the "FDA") seeking a Type C meeting with the FDA during the week of October 6th, 2025.
Positive
Proactive Investors
3 weeks ago
Medicus Pharma expands pipeline with Antev acquisition - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's latest strategic developments. Bokhari discussed the definitive agreement to acquire Antev, a UK-based company advancing clinical programs for two indications.
Positive
Seeking Alpha
3 weeks ago
Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment
Medicus Pharma offers high-risk, high-reward potential with its novel SkinJect patch for basal cell carcinoma and recent Antev acquisition expanding its pipeline. Strong insider/institutional backing and leadership with skin in the game are positives, but ongoing heavy dilution and cash burn are major concerns. FDA approval for SkinJect and Antev's assets is at least two years away; revenue generation is unlikely before 2027-2028, requiring investor patience.
Positive
Proactive Investors
1 month ago
Medicus to acquire UK biotech Antev in share deal worth up to $65m
Medicus Pharma (NASDAQ:MDCX) has agreed to acquire Antev, a UK-based drug developer working on treatments for prostate conditions, in a share-based deal that could be worth up to US$65 million in future milestone payments. Under the terms of the agreement, Antev shareholders will receive 2.67 million Medicus shares, equivalent to around 17% of the enlarged company, and worth $7.7 million at current prices.
Neutral
Newsfile Corp
1 month ago
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent Payments Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd.
Positive
Proactive Investors
1 month ago
Medicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studies
Medicus Pharma (NASDAQ:MDCX) said on Monday it has appointed Andrew Smith as chief operating officer, bringing on board a seasoned asset management executive as the company accelerates its clinical development programs in the US, Europe, and the Middle East. Smith, who most recently served as CEO of SR Asset Management until its sale in 2024, brings over 30 years of experience in financial and operational leadership.
Neutral
Newsfile Corp
1 month ago
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma (BCC) Using Novel Doxorubicin Containing Microneedle Arrays (D-MNA) Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chief Operating Officer.
Charts implemented using Lightweight Charts™